Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer.
Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM. Collins KAL, et al. Among authors: zawistowski js. Oncotarget. 2018 Jan 29;9(21):15480-15497. doi: 10.18632/oncotarget.24337. eCollection 2018 Mar 20. Oncotarget. 2018. PMID: 29643987 Free PMC article.
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.
Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, Sciaky N, Carey LA, Earp HS, Jin J, Johnson GL. Stuhlmiller TJ, et al. Among authors: zawistowski js. Cell Rep. 2015 Apr 21;11(3):390-404. doi: 10.1016/j.celrep.2015.03.037. Epub 2015 Apr 9. Cell Rep. 2015. PMID: 25865888 Free PMC article.
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL. Zawistowski JS, et al. Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20. Cancer Discov. 2017. PMID: 28108460 Free PMC article. Clinical Trial.
Landscaping a chromatin response to MEK inhibition.
Zawistowski JS, Goulet DR, Johnson GL. Zawistowski JS, et al. Cell Cycle. 2017 Apr 18;16(8):731-732. doi: 10.1080/15384101.2017.1302232. Epub 2017 Mar 13. Cell Cycle. 2017. PMID: 28287892 Free PMC article. No abstract available.
Pharmacologic targeting of drug-induced enhancers.
Zawistowski JS, Bevill SM, Johnson GL. Zawistowski JS, et al. Oncoscience. 2017 Jun 22;4(5-6):43-44. doi: 10.18632/oncoscience.354. eCollection 2017 May. Oncoscience. 2017. PMID: 28781985 Free PMC article. No abstract available.
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.
Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, Johnson GL, Jensen BC. Stuhlmiller TJ, et al. Among authors: zawistowski js. J Am Heart Assoc. 2017 Oct 19;6(10):e006635. doi: 10.1161/JAHA.117.006635. J Am Heart Assoc. 2017. PMID: 29051215 Free PMC article.
32 results